Fig. 1: Tau pathology and its spread are significantly reduced after neuronal APOE4 removal.
From: Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
a, Representative images of p-tau staining with AT8 antibody in the hippocampus of 10-month-old PS19-fE4 and PS19-fE3 mice with and without Cre (scale bar, 500 µm). b, Quantification of the percent p-tau (AT8) coverage area in the hippocampus of 10-month-old PS19-fE4 and PS19-fE3 mice with or without Cre. c, Representative images of Thio-S staining in the hippocampus of 10-month-old PS19-fE4 and PS19-fE3 mice with and without Cre (scale bar, 500 µm). d, Quantification of the number of Thio-S-positive cells in the hippocampus of 10-month-old PS19-fE4 and PS19-fE3 mice with or without Cre. e,f, Representative images of anti-p-tau (AT8, green) and anti-TUJ1 (red) western blots in RAB (e) and RIPA (f) fractions of hippocampal tissue lysates from 10-month-old PS19-fE4 and PS19-fE3 mice with or without Cre. g,h, Quantification of AT8-positive p-tau levels relative to TUJ1 measured by western blot analysis in RAB (g) and RIPA (h) fractions of the hippocampal lysates from 10-month-old PS19-fE4 and PS19-fE3 mice with or without Cre. i, Experimental design of tau propagation study following unilateral hippocampal injection of AAV2-Tau-P301S in fE mice with and without Cre. j, Representative images of human tau immunostaining (HT7) of a fE4 mouse brain 12 weeks after injection, with the injection site indicated by the black dot and a notch to distinguish the non-injected side (scale bar, 1 mm). k, Representative image of GFP immunostaining of a 10-month-old fE4 mouse 2 weeks after a unilateral injection with AAV2-GFP (scale bar, 900 µm). l, Representative images of human tau immunostaining (HT7) on the non-injected hippocampal side of 13-month-old fE mice with and without Cre (scale bar, 500 µm). m, Quantification of the average number of HT7 (human tau)-positive cells in each hippocampal slice on the non-injected hippocampal side of 13-month-old fE mice with or without Cre 12 weeks after injection. n, Representative images of p-tau immunostaining (AT8) on the non-injected hippocampal side of 13-month-old fE mice with or without Cre (scale bar, 500 µm). o, Quantification of the average number of AT8 (p-tau)-positive cells in each hippocampal slice on the non-injected hippocampal side of 13-month-old fE mice with or without Cre 12 weeks after injection. For quantifications in b,d, PS19-fE4: No Cre, n = 25; Syn1-Cre, n = 17; PS19-fE3: No Cre, n = 20; Syn1-Cre, n = 15. For quantifications in g,h, PS19-fE4: No Cre, n = 21; Syn1-Cre, n = 18; PS19-fE3: No Cre, n = 17; Syn1-Cre, n = 11.Quantified data in m,o are n = 8 mice per genotype and data in b,d,g,h,m,o are represented as mean ± s.e.m., one-way analysis of variance (ANOVA) with Tukey’s post hoc multiple comparisons test. Source data.
